Show simple item record

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorRubio-Perez, Carlota
dc.contributor.authorGonzalez-Roca, Eva
dc.contributor.authorSeguí, Elia
dc.contributor.authorAngelats, Laura
dc.contributor.authorParé, Laia
dc.contributor.authorSanfeliu Torres, Esther
dc.contributor.authorVillacampa Javierre, Guillermo
dc.contributor.authorVivancos, Ana
dc.date.accessioned2025-04-01T08:56:10Z
dc.date.available2025-04-01T08:56:10Z
dc.date.copyright2024
dc.date.issued2025-01
dc.identifier.citationAngelats L, Paré L, Rubio-Perez C, Sanfeliu E, González A, Seguí E, et al. Linking tumor immune infiltration to enhanced longevity in recurrence-free breast cancer. ESMO Open. 2025 Jan;10(1):104109.
dc.identifier.issn2059-7029
dc.identifier.urihttp://hdl.handle.net/11351/12861
dc.descriptionBreast cancer; Immune gene expression; Longevity
dc.description.abstractBackground The infiltration of tumor-infiltrating B cells and plasma cells in early-stage breast cancer has been associated with a reduced risk of distant metastasis. However, the influence of B-cell tumor infiltration on overall patient survival remains unclear. Materials and methods This study explored the relationship between an antitumor immune response, measured by a 14-gene B-cell/immunoglobulin (IGG) signature, and mortality risk in 9638 breast cancer patients across three datasets. Associations with tumor subtype, stage, and age were examined. IGG was characterized using spatial GeoMx profiling and single-cell RNA sequencing, and its relationship with tertiary lymphoid structures (TLSs) was evaluated. The predictive value of each of the 14 IGG genes for B-cell receptor (BCR) and T-cell receptor (TCR) clonality and longevity was also assessed, along with its association with longevity in other cancer types. Results High IGG signature expression was significantly associated with a 41%-47% reduction in death risk in breast cancer survivors (P < 0.001), regardless of age, tumor stage, or subtype. Similar associations were observed in other cancers, including melanoma. In breast cancer, the IGG signature was significantly linked to overall survival without relapse in patients aged 41-70 years at diagnosis. Additionally, IGG expression correlated with the presence of TLSs and higher B- and T-cell polyclonality. A specific subset of seven IGG genes strongly correlated with BCR and TCR clonality, with predictive power for identifying clonality and improved longevity, especially when combining two of these genes. Conclusions This study uncovers a significant link between immune gene expression in tumors and extended longevity in breast cancer survivors, even in the absence of recurrence. The IGG signature, particularly its key gene subset, emerges as a powerful marker of sustained antitumor immunity and overall patient fitness. These findings pave the way for personalized treatment strategies that enhance both survival and long-term health outcomes.
dc.language.isoeng
dc.publisherElsevier
dc.relation.ispartofseriesESMO Open;10(1)
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.sourceScientia
dc.subjectMama - Càncer - Aspectes immunològics
dc.subjectCèl·lules B
dc.subjectResposta immunitària
dc.subjectMama - Càncer - Aspectes Genètics
dc.subject.meshBreast Neoplasms
dc.subject.mesh/immunology
dc.subject.meshB-Lymphocytes
dc.subject.meshLymphocytes, Tumor-Infiltrating
dc.titleLinking tumor immune infiltration to enhanced longevity in recurrence-free breast cancer
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1016/j.esmoop.2024.104109
dc.subject.decsneoplasias de la mama
dc.subject.decs/inmunología
dc.subject.decslinfocitos B
dc.subject.decslinfocitos infiltrantes de tumor
dc.relation.publishversionhttps://doi.org/10.1016/j.esmoop.2024.104109
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Angelats L] Translational Genomics and Targeted Therapies in Solid Tumors group, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain. Institute of Cancer and Blood Diseases, Hospital Clinic of Barcelona, Barcelona, Spain. Department of Medicine, University of Barcelona, Barcelona, Spain. [Paré L] Reveal Genomics, Barcelona, Spain. [Rubio-Perez C, Seguí E] Translational Genomics and Targeted Therapies in Solid Tumors group, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain. Institute of Cancer and Blood Diseases, Hospital Clinic of Barcelona, Barcelona, Spain. [Sanfeliu E] Translational Genomics and Targeted Therapies in Solid Tumors group, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain. Department of Pathology, Hospital Clinic of Barcelona, Barcelona, Spain. [González A] Department of Pathology, Hospital Clinic of Barcelona, Barcelona, Spain. Immunogenetics and Immunotherapy in Autoinflammatory and Immune Responses, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain. [Villacampa G] Statistics Unit, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Vivancos A] Cancer Genomics Group, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain
dc.identifier.pmid39765189
dc.identifier.wos001412312100001
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record